Phillips K, Munster D J, Allardyce R A, Bagshaw P F
Department of Surgery, Christchurch School of Medicine, New Zealand.
J Clin Pathol. 1993 Apr;46(4):372-3. doi: 10.1136/jcp.46.4.372.
The urease inhibitor acetohydroxamic acid (AHA) was assessed for its bacteriostatic and bactericidal effects on Helicobacter pylori. For eight isolates of H pylori, the minimum inhibitory concentration (MIC) was either 200 mg/l or 400 mg/l. Interactions between AHA and antimicrobial drugs used to treat H pylori were also determined. For most isolates AHA reduced the MIC for colloidal bismuth subcitrate (CBS), tetracycline, metronidazole, and amoxicillin. In a few isolates, however, AHA increased the minimum bactericidal concentration (MBC) for these antimicrobial treatments. In vitro AHA is active against H pylori and it interacts with other agents directed against H pylori.
对脲酶抑制剂乙酰氧肟酸(AHA)针对幽门螺杆菌的抑菌和杀菌作用进行了评估。对于8株幽门螺杆菌分离株,最低抑菌浓度(MIC)为200mg/l或400mg/l。还确定了AHA与用于治疗幽门螺杆菌的抗菌药物之间的相互作用。对于大多数分离株,AHA降低了枸橼酸铋钾(CBS)、四环素、甲硝唑和阿莫西林的MIC。然而,在少数分离株中,AHA增加了这些抗菌治疗的最低杀菌浓度(MBC)。在体外,AHA对幽门螺杆菌有活性,并且它与其他针对幽门螺杆菌的药物相互作用。